title: Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women.
abstract: Insulin sensitivity (Si), glucose tolerance, and lipid metabolism were investigated in osteopenic postmenopausal women before and after 6 months of treatment with raloxifene (60 mg/d) or placebo. In a group of women (n = 34), glucose metabolism was evaluated by means of an oral glucose tolerance test (75 g). In another group of women (n = 24), Si and peripheral glucose utilization not dependent on insulin were evaluated by means of a frequently sampled iv glucose tolerance test associated with the minimal model method. No metabolic modification was observed in women receiving placebo. Raloxifene did not significantly modify high density lipoprotein-cholesterol and triglycerides, whereas it significantly decreased low density lipoprotein (LDL) cholesterol (4.84 +/- 0.34 mmol/liter vs. 3.83 +/- 0.49 mmol/liter; P = 0.014) and LDL/high density lipoprotein cholesterol ratio (3.21 +/- 0.31 mmol/liter vs. 2.46 +/- 0.44 mmol/liter; P = 0.012). Fasting levels and responses to the oral glucose tolerance test of glucose, insulin, C-peptide, and C-peptide/insulin were not modified by raloxifene. Similarly, raloxifene did not modify Si (4.22 +/- 4.1 vs. 5.13 +/- 1.75), or insulin (0.025 +/- 0.003 vs. 0.019 +/- 0.002). The present data show that in osteopenic postmenopausal women raloxifene reduces LDL levels but does not modify insulin sensitivity and glucose metabolism.
authors.affiliation: Institute of Obstetrics and Gynecology, University of Modena, 41100 Modena, Italy. cagnacci@unimo.it
authors.forename: Angelo
authors.initials: A
authors.lastname: Cagnacci
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Paoletti
authors.forename: Annalisa
authors.initials: A
authors.lastname: Zanni
authors.forename: Serenella
authors.initials: S
authors.lastname: Arangino
authors.forename: Giulietta
authors.initials: G
authors.lastname: Ibba
authors.forename: Marisa
authors.initials: M
authors.lastname: Orrù
authors.forename: Gian Benedetto
authors.initials: GB
authors.lastname: Melis
authors.forename: Annibale
authors.initials: A
authors.lastname: Volpe
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D001851:Bone Diseases, Metabolic / Q000097:blood* / Q000188:drug therapy*; D002096:C-Peptide / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood*; D007558:Italy; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000188:drug therapy*; D010919:Placebos; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D044465:White People
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D010919:Placebos; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D004958:Estradiol; D005640:Follicle Stimulating Hormone